52-Week Lows: A Screening Signal, Not a Buy Indication
We view 52-week lows as a catalyst for inquiry, rather than a cue to purchase. A stock might be considered “inexpensive” for valid reasons—and may never recapture its previous peaks.
Weakness in price can indicate negative sentiment warranting a closer examination
Steer clear of price anchoring (“it previously was $100, so it will return”)
An optimal scenario combines solid fundamentals with a negative narrative that you can accurately assess
The “Ratings Fallacy” and the Influence of Perception
Analyst ratings may provide insights, but they rely on models + assumptions. If the foundational assumption is flawed, the “opportunity” may never arise.
Valuation models might identify a stock as undervalued… even if the market disagrees
A “5-star” rating does not shield you from a dividend cut or a prolonged decline
The objective is to distinguish fear-induced selling from deterioration based on fundamentals
Healthcare at a Low: Strong Companies, Genuine Policy Risks
Two prominent healthcare firms display robust historical fundamentals—but both face headline risks and uncertainties.
UnitedHealth (UNH):
What we appreciate: vertical integration (insurance + care provision), extensive history of successful execution
Reasons for decline: accumulation of unfavorable news + cost pressures + uncertainties regarding Medicare Advantage reimbursements
Our perspective: high risk / high reward, but not a current position for him
Zoetis (ZTS):
What we value: category leader in animal health, persistent veterinarian loyalty